StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Free Report) in a research note published on Sunday. The brokerage issued a sell rating on the biotechnology company’s stock.
Separately, Roth Capital cut shares of Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd.
Check Out Our Latest Research Report on Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals Stock Performance
Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.36. Cyclacel Pharmaceuticals had a negative return on equity of 1,901.11% and a negative net margin of 18,150.00%. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.01 million. On average, analysts forecast that Cyclacel Pharmaceuticals will post -1.95 earnings per share for the current year.
Institutional Trading of Cyclacel Pharmaceuticals
A hedge fund recently bought a new stake in Cyclacel Pharmaceuticals stock. Armistice Capital LLC acquired a new stake in shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC – Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned about 9.18% of Cyclacel Pharmaceuticals as of its most recent filing with the SEC. Institutional investors own 23.58% of the company’s stock.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.
See Also
- Five stocks we like better than Cyclacel Pharmaceuticals
- What Investors Need to Know to Beat the Market
- Beyond NVIDIA: Top 5 Semiconductor Stocks to Watch for 2025
- How to Use Stock Screeners to Find Stocks
- Netflix Is On Track To Hit $1,000 By Christmas
- Most Volatile Stocks, What Investors Need to Know
- UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.